LENZ Therapeutics, Inc.
LENZ (Nasdaq: LENZ) is a commercial pharmaceutical company focused on developing and commercializing therapies to improve vision. Its lead product, VIZZ, is a once-daily prescription eye drop approved in the United States to treat presbyopia, an age-related loss of near vision; the company sells it to consumers… From the company’s description.
In fiscal 2025, LENZ Therapeutics, Inc. reported revenue of $19.09M and a net loss of $82.13M. Its operating margin was −477.5%, and operations used $69.17M in cash. Over the twelve months to Sep 30, 2026, revenue was $12.36M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What LENZ Therapeutics, Inc. does
In the company’s own words
LENZ (Nasdaq: LENZ) is a commercial pharmaceutical company focused on developing and commercializing therapies to improve vision. Its lead product, VIZZ, is a once-daily prescription eye drop approved in the United States to treat presbyopia, an age-related loss of near vision; the company sells it to consumers through retail pharmacies and an e-pharmacy partner and promotes it to optometrists and ophthalmologists. LENZ launched VIZZ in the United States in 2025 and is pursuing international licensing and distribution partnerships. It has agreements covering Greater China, South Korea and Southeast Asia, Canada, and nine Middle Eastern countries, and continues to seek partners in other markets. LENZ operates as a single business focused on VIZZ, with no reportable segments described. Its commercial activities target eye care professionals and presbyopes, and U.S. sales are made on a self-pay basis without third-party reimbursement. VIZZ contains aceclidine and is supplied in preservative-free, single-dose vials. The company’s fiscal year ends December 31; the provided filing text does not include a headline annual revenue or employee figure. Its website is www.lenz-tx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SOLANA BEACH, CA
- Fiscal year end
- December
- CIK
- 1815776
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns LENZ Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · LENZ Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do LENZ Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of LENZ Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in LENZ Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”